Pulsus Group

Maya Barsky, MD, MSCI Joins the Center for Advanced Reproductive Services as a Lead Physician

Retrieved on: 
Tuesday, December 12, 2023
REI, Assistant, Brown University, Research, Fertility, Baylor University, University, Patient, Pulsus Group, Baylor College of Medicine, American College, ACOG, ASRM, PCOS, Reproductive medicine, Fertility preservation, Society, Meigs's syndrome, Ovarian reserve, Birth control, Infertility, Gynaecology

FARMINGTON, Conn., Dec. 12, 2023 /PRNewswire/ -- The Center for Advanced Reproductive Services, one of the leading family building programs in the country, announced Dr. Maya Barsky, reproductive endocrinologist, has joined as Lead Physician and Assistant Professor in the Department of Ob/Gyn at UConn School of Medicine.

Key Points: 
  • FARMINGTON, Conn., Dec. 12, 2023 /PRNewswire/ -- The Center for Advanced Reproductive Services, one of the leading family building programs in the country, announced Dr. Maya Barsky, reproductive endocrinologist, has joined as Lead Physician and Assistant Professor in the Department of Ob/Gyn at UConn School of Medicine.
  • "I am very fortunate to be a part of such a respected and successful program as the Center for Advanced Reproductive Services."
  • Dr. Barsky is available to connect with patients via telehealth appointments effective immediately, with in-person appointments beginning in January 2024.
  • Prior to joining The Center for Advanced Reproductive Services, she was part of a private fertility practice in Austin, TX for several years.

Switch Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Carbon, Tissue, Amgen, University of Bristol, University of East London, Migraine, University, Senior, Doctor of Philosophy, Schizophrenia, CSO, P. R. Mallory and Co Inc, Western University, Rochester, Thomas Jefferson University, Pulsus Group, Nitric oxide, Coronavirus Scientific Advisory Board, DRS, Janssen, Physiology, Research, Iron monosilicide, Johns Hopkins School of Medicine, RNA, Genentech, Princeton University, Drexel University, CNS, Conditional, Pain, Discovery, Lilly, Molecular neuroscience, Outline of health sciences, Novo Nordisk, RNA interference, Merck, Therapy, Oligonucleotide, Western University of Health Sciences, Disease, Research fellow, Pharmaceutical industry, Erenumab, Neuroscience, Chemistry, Biology

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.
  • Marc Abrams, David Bredt and James Treanor to our company’s Scientific Advisory Board,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, they bring decades of experience in CNS and RNA therapies and we’re thrilled for them to join the Switch Therapeutics team.
  • Dr. Abrams spent the first 17 years of his career at Merck and Co., Inc in scientific positions of increasing responsibility.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW BOARD MEMBER JAMES G. KRUEGER, MD, PhD

Retrieved on: 
Friday, April 7, 2023
ASA, Therapy, Senior, Research fellow, Pulsus Group, Rockefeller University, Dermatology, Research, Doctor of Philosophy, Psoriasis, American Board of Commissioners for Foreign Missions, American Board of Dermatology, Diagnosis, Phenotype, Laboratory, Skin, MD

NEW YORK, April 7, 2023 /PRNewswire/ -- American Skin Association (ASA) announced today that James G. Krueger, MD, PhD, will join its Board of Directors.

Key Points: 
  • NEW YORK, April 7, 2023 /PRNewswire/ -- American Skin Association (ASA) announced today that James G. Krueger, MD, PhD, will join its Board of Directors.
  • He also serves as Senior Attending Physician and Co-Director of the Center for Clinical and Translational Science and as Chief Executive Officer of The Rockefeller University Hospital.
  • "We are thrilled to announce the addition of Dr. James Krueger to our Board of Directors.
  • Dr. Krueger has practiced at Rockefeller University Hospital for 25 years and is certified by the American Board of Dermatology.

Sequencing Reagents Market To Reach USD 15.9 Billion By 2028 With A CAGR Of 16.4%| Valuates Reports

Retrieved on: 
Friday, February 3, 2023
DNA, Mutation, Pulsus Group, DNA sequencing, Pharmacology, NGS, Third-generation sequencing, Projection, Medication, Oncology, Patient, RNA, Research, USD, Growth, Neoplasm, Sanger sequencing, Cancer, Fine chemical, Medical imaging

The global Sequencing Reagents Market size is estimated to be worth USD 5.5 billion in 2021 and is forecast to a readjusted size of USD 15.9 billion by 2028 with a CAGR of 16.4% during the review period.

Key Points: 
  • The global Sequencing Reagents Market size is estimated to be worth USD 5.5 billion in 2021 and is forecast to a readjusted size of USD 15.9 billion by 2028 with a CAGR of 16.4% during the review period.
  • The two main variables that will affect the growth of the sequencing reagents market are advances in sequencing techniques and falling costs for genetic sequencing.
  • Additionally, the Sequencing Reagents market is expanding at an accelerated rate due to the spike in the usage of sequencing techniques and different developments.
  • This factor is expected to drive the growth of the Sequencing Reagents market.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW MEDICAL ADVISORY COMMITTEE CO-CHAIR JAMES G. KRUEGER, MD, PHD

Retrieved on: 
Monday, January 30, 2023
Laboratory, ASA, Rockefeller University, Diagnosis, Research fellow, Pulsus Group, Dermatology, Chairperson, American Board of Commissioners for Foreign Missions, Psoriasis, Skin, Doctor of Philosophy, Therapy, Phenotype, American Board of Dermatology, Research, Senior, Pharmaceutical industry, Medical device, MD

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- American Skin Association (ASA) announced today that James G. Krueger, MD, PhD, will join its Medical Advisory Committee as Co-Chair.

Key Points: 
  • NEW YORK, Jan. 30, 2023 /PRNewswire/ -- American Skin Association (ASA) announced today that James G. Krueger, MD, PhD, will join its Medical Advisory Committee as Co-Chair.
  • "We are thrilled to announce the addition of Dr. James Krueger to our Medical Advisory Committee.
  • "We welcome Dr. Krueger to our Medical Advisory Committee!
  • Dr. Krueger has practiced at Rockefeller University Hospital for 25 years and is certified by the American Board of Dermatology.

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, January 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, National university, Immunology, TRAAC, Memorial Sloan Kettering Cancer Center, Evaluation, Biochemistry, Therapy, Immunotherapy, Incyte, Faculty, Rockefeller University, AstraZeneca, Pediatrics, Patient, Jasper, Yale University, George Washington University, Cancer, Clinical trial, BMS, Multimedia, TLR9, Pulsus Group, Bristol Myers Squibb, Pharmaceutical industry, Tallac Records

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.

Key Points: 
  • Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.
  • View the full release here: https://www.businesswire.com/news/home/20230119005166/en/
    Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer (Graphic: Business Wire)
    “We are especially pleased to welcome Kevin to Tallac’s leadership team at a time when the Company is advancing novel immunotherapeutic agents in early clinical development,” said Hong I. Wan, Ph.D., president, CEO and co-founder of Tallac Therapeutics.
  • “Kevin brings a wealth of expertise as a seasoned drug developer with a proven track record of clinical trial planning and execution.
  • Prior to that, he was chief medical officer at NextCure, Inc., a biotechnology company developing immunotherapy-based biologics for cancer and other diseases.

Ventyx Biosciences to Host R&D Event on January 26, 2023

Retrieved on: 
Thursday, January 5, 2023
Doctor of Philosophy, Rockefeller University, Inflammation, Pulsus Group, MD, Pharmaceutical industry

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m.

Key Points: 
  • ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m.
  • ET.
  • The event will highlight key aspects of Ventyx’s clinical-stage and discovery programs.
  • A webcast replay will also be available on this website shortly after conclusion of the event.

Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation

Retrieved on: 
Tuesday, October 25, 2022
Psoriasis, Skin, U.S. Securities and Exchange Commission, Dermatology, RBS, IL, SEC, Growth, Ophthalmology, Pulsus Group, Laboratory, CXCL1, Keratinocyte, NIH, Cell, Security (finance), Secondary research, Senior, Infection, Trial of the century, Company, Drug discovery, Doctor of Philosophy, MD, National, Legislation, Convoy HX 156, Rockefeller University, Immunotherapy, Safety, HX, GLOBE, P.O, Interferon, Forward-looking statement, Hematology, Center, OTCQB, Kruger, IL-19, Pharmaceutical industry

They also hope to determine PH-10s interaction with and uptake by blood leukocytes, because these cells mediate inflammatory skin diseases and control or protect against some types of skin cancers.

Key Points: 
  • They also hope to determine PH-10s interaction with and uptake by blood leukocytes, because these cells mediate inflammatory skin diseases and control or protect against some types of skin cancers.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs).
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.
  • Risks, uncertainties, and assumptions include those discussed in the Companys filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

Elsevier expands Open Access options for Cell Press Journals from January 2021

Retrieved on: 
Friday, December 18, 2020
Publishing, Education, Academia, Academic publishing, Electronic publishing, Elsevier, Open access, Pulsus Group, Hybrid open-access journal, Predatory publishing

As one of the fastest-growing open access publishers in the world, nearly all of Elsevier's 2,600 journals now enable open access publishing, including 500 fully open access journals.

Key Points: 
  • As one of the fastest-growing open access publishers in the world, nearly all of Elsevier's 2,600 journals now enable open access publishing, including 500 fully open access journals.
  • From January 2021, all authors will have the option to publish open access across the entire range of the highly regarded and influential Cell Press family of journals.
  • Overall, the Cell Press journals will offer open access publishing at APCs starting from 1,400 / 1,500 / $1,750.
  • We are pleased to expand open access publishing options for Cell Press journals for authors whilst maintaining the highest standards of quality and editorial rigour that our journals represent."

Elsevier expands Open Access options for Cell Press Journals from January 2021

Retrieved on: 
Friday, December 18, 2020
Publishing, Education, Academia, Academic publishing, Electronic publishing, Elsevier, Open access, Pulsus Group, Hybrid open-access journal, Predatory publishing

As one of the fastest-growing open access publishers in the world, nearly all of Elsevier's 2,600 journals now enable open access publishing, including 500 fully open access journals.

Key Points: 
  • As one of the fastest-growing open access publishers in the world, nearly all of Elsevier's 2,600 journals now enable open access publishing, including 500 fully open access journals.
  • From January 2021, all authors will have the option to publish open access across the entire range of the highly regarded and influential Cell Press family of journals.
  • Overall, the Cell Press journals will offer open access publishing at APCs starting from 1,400 / 1,500 / $1,750.
  • We are pleased to expand open access publishing options for Cell Press journals for authors whilst maintaining the highest standards of quality and editorial rigour that our journals represent."